Paraxel Receives BioSingapore Award for Best Performing CRO
Boston, MA, March 23, 2009 – PAREXEL International Corporation (NASDAQ:PRXL), a leading global biopharmaceutical services provider, today announced that the Company has received the Best Performing Clinical Research Organization (CRO) Award from BioSingapore, an industry association for life sciences businesses encouraged by the Economic Development Board of Singapore. The award was presented to PAREXEL at the BioSingapore Asia/Pacific Biotechnology Awards 2009 Gala Dinner held March 17, 2009 during the BioMedical Asia Conference in Singapore. BioSingapore's Awards celebrate the contributions of companies and individuals in the life sciences industry to advancing the scientific enterprise in the Asia/Pacific region.
According to Michael Entzeroth, Ph.D., Chairman of BioSingapore, "The BioSingapore Award for Best Performing CRO, which was reviewed by an independent panel of peer judges, honors PAREXEL for its focus on supporting clinical development throughout the Asia/Pacific region. PAREXEL is recognized for the broad spectrum of services provided by the Company, the competitive edge it has created in this geography, and its international reputation for speed and high quality. BioSingapore is pleased to commend PAREXEL for its overall outstanding performance and contributions to advancing the clinical research environment in the Asia/Pacific region.”
"PAREXEL is honored to be chosen as the Best Performing CRO by BioSingapore,” said Mark A. Goldberg, M.D., Chief Operating Officer of
PAREXEL International. "PAREXEL has had a long-term commitment to providing high quality clinical development services in the Asia/Pacific region. As outsourced clinical research experiences accelerated growth in this geography, we look forward to continuing to provide both global capabilities and local expertise to meet client needs in developing safe and efficacious treatments. This achievement would not have been possible without the dedication of our talented employees and the ongoing support of our valued clients in the region.”
For more information about PAREXEL's capabilities in the Asia/Pacific region visit http://www.parexel.com/emerging-regions.html. More information about BioSingapore can be found at http://www.biosingapore.org.sg/.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
